Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
NCT Number: NCT04111926
This is a 3-year follow-up of patients enrolled in a previous randomized controlled trial which showed that intraoperative dexmedetomidine reduced delirium in elderly patients after major non-cardiac surgery. The purpose of this study is to clarify the effects of intraoperative dexmedetomidine on long-term outcomes of these patients.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Phase 4
Beijing, Beijing Municipality, 100034, China
Dexmedetomidine is a highly selective α-2-receptor agonist with sedative, analgesic and anxiolytic effects. When used as an supplement during general anaesthesia, it reduces the consumption of the anaesthetics and relieves surgery-related stress response and inflammation. In a recent randomized ontrolled trial of the applicants, 620 elderly patients who underwent major non-cardiac surgery were randomized to receive dexmedetomidine or normal saline during general anesthesia. The results showed that use of dexmedetomidine reduced delirium (5.5% [17/309] with dexmedetomidine vs. 10.2% [32/310] with placebo, P=0.026) and 30-day non-delirium complications (9.4% [60/309] with dexmedetomidine vs. 26.1% [81/310] with placebo, P=0.047) after surgery.
The effects of intraoperative dexmedetomidine on long-term outcomes after surgery remains unclear. In another study of the applicants, use of low-dose dexemeditomidine in ICU patients after surgery increased survival up to 2 years and improve quality of life in 3-year survivors. On the contrary, it was reported in a retrospective study that intraoperative use of dexmedetomidine was associated with shortened overall survival in patients after lung cancer surgery. Therefore, it is urgent to clarify the impact of intraoperative dexemeditomidine on long-term outcomes of patients undergoing major surgery, especially those undergoing cancer surgery.
This study is a 3-year follow-up of patients who were enrolled in a randomzied controlled trial of the applicants in order to clarify the effects of intraoperative dexmedetomidine on long-term outcomes after surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
Other names: Dexmedetomidine Hydrochloride
Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
Other names: Normal saline
Time frame: Up to 3 years after surgery.
Overall survival within 3 years after surgery
Time frame: Up to 3 years after surgery.
Recurrence-free survival within 3 years after surgery.
Time frame: Up to 3 years after surgery.
Cancer-specific survival within 3 years after surgery.
Time frame: Up to 3 years after surgery.
Rate of new-onset disease or hospital readmission within 3 years after surgery.
Time frame: At 3 years after surgery.
Quality of life is assessed with the World Health Organization Quality of Life-Brief Version. It assesses the quality of life at 4 domains, i.e., physical, psychological, social relationships, and environment. The score of each domain ranges from 0 to 100, with higher score indicating better quality of life.
Peking University First Hospital
Other
Impact of Intraoperative Dexmedetomidine on Long-term Outcomes in Elderly Patients After Major Non-cardiac Surgery: 3-year Follow-up of a Randomised Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07581236
Carcinoma, Carcinoma, Squamous Cell
Guangzhou, Guangdong, China
View Trial DetailsNCT07521397
Adjuvant Chemotherapy, Breast Cancer
Athens, Greece
View Trial DetailsNCT04947020
Colorectal Neoplasms, Digestive System Diseases
Krakow, Malopolska, Poland
View Trial DetailsNCT05796700
Cost, Overall Survival
View Trial Details